Why do child contacts of multidrug-resistant tuberculosis not come to the assessment clinic?
K Zimri, A C Hesseling, P Godfrey-Faussett...
https://pubmed.ncbi.nlm.nih.gov/26392955/Actively Recruiting
Led by Azienda Sanitaria Locale CN2 Alba-Bra · Updated on 2026-02-17
3300
Participants Needed
1
Research Sites
13 weeks
Total Duration
This observational study examines how breast density affects the accuracy and outcomes of mammographic screening for breast cancer within the regional Prevenzione Serena program at ASL CN2. It focuses on women aged 45 to 75 years who underwent routine screening between September 2023 and May 2024. The study evaluates the association between breast density categories BI-RADS A-D and the frequency of recalls for additional diagnostic tests, aiming to understand how dense breast tissue impacts detection and false-positive rates. The research includes an internal validation of Insight BD, an automated software used to measure breast density. This validation involves technical testing with a mammography phantom and comparisons of the softwares BI-RADS classifications with assessments from two radiologists. No treatments or interventions are given, as data are collected retrospectively from clinical records. The study also explores how factors like menopausal status, hormone therapy, and family history relate to breast density and screening outcomes. Participants data will be analyzed for recall rates for second-level exams such as ultrasound or MRI, false-positive findings, and breast density distribution. Researchers will monitor the softwares accuracy and agreement with radiologists readings. The primary outcome is the recall rate by breast density category during the screening period. The study aims to inform future personalized screening guidelines and improve breast cancer detection strategies for women with dense breasts.
CONDITIONS
Breast Density Impact on Mammographic Screening for Breast Cancer Diagnosis
F
Francesco Lucio, Principal Investigator
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Azienda Sanitaria Locale CN2 Alba-Bra
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) during routine mammographic screening
Duration - Approximately 7 months
Participants undergo routine mammographic screening to assess breast density and identify any need for second-level diagnostic examinations.
1 mammographic screening visit
Duration - Up to 2 years after screening period
Participants' screening data, including breast density and recall rates, are observed retrospectively to evaluate screening performance and associations with clinical factors.
No additional visits; data collection is retrospective
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
K Zimri, A C Hesseling, P Godfrey-Faussett...
https://pubmed.ncbi.nlm.nih.gov/26392955/Kimberly M Ray, Elissa R Price, Bonnie N Joe
https://pubmed.ncbi.nlm.nih.gov/25615746/K Pesce, M Tajerian, M J Chico...
https://pubmed.ncbi.nlm.nih.gov/32493654/Arnau Oliver, Meritxell Tortajada, Xavier Lladó...
https://pubmed.ncbi.nlm.nih.gov/25720749/Amanda Eng, Zoe Gallant, John Shepherd...
https://pubmed.ncbi.nlm.nih.gov/25239205/Abra M Jeffers, Weiva Sieh, Jafi A Lipson...
https://pubmed.ncbi.nlm.nih.gov/27598536/Soudabeh Fazeli Dehkordy, Ruth C Carlos
https://pubmed.ncbi.nlm.nih.gov/27814815/Christine N Damases, Patrick C Brennan, Claudia Mello-Thoms...
https://pubmed.ncbi.nlm.nih.gov/26514436/Blanca Martínez-Navarro, Ruth Sanchis, Esther Asedegbega-Nieto...
https://pubmed.ncbi.nlm.nih.gov/32455643/Jason Sheehan
https://pubmed.ncbi.nlm.nih.gov/35348987/Azienda Sanitaria Locale CN2 Alba-Bra
Lead Sponsor